Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.

The pharmacogenomics journal - 1 Apr 2011

Bergmann T K, Brasch-Andersen C, Gréen H, Mirza M, Pedersen R S, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg L E, Peterson C, Vach W, Karlsson M O, Brosen K

Abstract excerpt

The primary purpose of this study was to evaluate the effect of CYP2C8*3 and three genetic ABCB1 variants on the elimination of paclitaxel. We studied 93 Caucasian women with ovarian cancer treated with paclitaxel and carboplatin. Using sparse sampling and nonlinear mixed effects modeling, the individual clearance of unbound paclitaxel was estimated from total plasma paclitaxel and Cremophor EL. The geometric...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to ATP Binding Cassette Transporter, Subfamily B

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ATP Binding Cassette Transporter, Subfamily B, Member 1

Share to Carboplatin

Share to Cytochrome P-450 CYP2C8

Share to Ovarian Neoplasms

Share to Paclitaxel

Share to Population

Source

Identifiers

PMID: 20368717
DOI: 10.1038/tpj.2010.19

Genes

ABCB1
ABCC1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer.PMID 20368717Read ↗

Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.Semantic proximity Read ↗

Impact of ABCB1 variants on neutrophil depression: a pharmacogenomic study of paclitaxel in 92 women with ovarian cancer.Semantic proximity Read ↗

A pharmacogenetic predictive model for paclitaxel clearance based on the DMET platform.Semantic proximity Read ↗

Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.Semantic proximity Read ↗

Genome-wide association study of paclitaxel and carboplatin disposition in women with epithelial ovarian cancer.Semantic proximity Read ↗

Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.Semantic proximity Read ↗

Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.Semantic proximity Read ↗

Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.Semantic proximity Read ↗

CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel.Semantic proximity Read ↗

Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.Semantic proximity Read ↗

Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics.Semantic proximity Read ↗

Paclitaxel sensitivity in relation to ABCB1 expression, efflux and single nucleotide polymorphisms in ovarian cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.